Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients

Phase 2

• Conditions: Acute Myocardial Infarction
• Interventions: Drug: Eptifibatide

• Registration Number: NCT00945308
• Lead Sponsor: Assaf-Harofeh Medical Center

Brief Summary

The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct intracoronary injection, promotes (in vitro) clot disaggregation. It remains unclear if it is of superior benefit than the routine intravenous administration of these agents.

In patients presenting with acute myocardial infarction, and undergoing primary coronary intervention, intracoronary administration of Eptifibatide may increase local drug concentration by several orders of magnitude and promote clot disaggregation with a minimal increase in systemic drug concentration, and in that way enhancing myocardial perfusion and survival.

Detailed Description

Patients will be randomized, prospectively, single blinded into one of two arms:1)intravenous administration of Eptifibatide and 2) intracoronary administration. The primary end-point will be the angiographic achievement of TIMI 3 flow at the infarct related artery and TIMI myocardial perfusion grade (blush) and the electrocardiographic surrogate of myocardial perfusion the ST segment resolution.

The secondary end-points will be the occurrence of bleeding or hemorrhagic complication according to TIMI classification and the LVEF at one month compared with baseline

Study Timeline

• Status Verified: 2009-07
• Study First Submitted: 2009-07-08
• Study First Submitted QC: 2009-07-23
• Last Update Submitted: 2009-07-23
• Study First Posted: 2009-07-24
• Last Update Posted: 2009-07-24
• Study Start: 2009-08
• Primary Completion: 2010-02
• Study Completion: 2010-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Acute myocardial infarction candidate for primary coronary angioplasty, presenting within 12 hours of onset of pain and ability to clearly identified only one infarct related artery.

Read More

Exclusion Criteria

• Contraindications for antiplatelet therapy such as bleeding disorders,
• Thrombocytopenia,
• Severe uncontrolled hypertension,
• Recent stroke (<6 months),
• Intracranial hemorrhage at any time
• Patients after recent major surgery (<30 days),
• Previous myocardial infarction
• Previous revascularization either by CABG or PCI and 9)patients presented with cardiogenic shock.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Eptifibatide (intravenous)	Eptifibatide	-
Eptifibatide (intracoronary)	Eptifibatide	-

Primary Outcome Measures

Name	Time	Method
Coronary angiography	At the time of the procedure

Secondary Outcome Measures

Name	Time	Method
Electrocardiogram	90 min after the procedure

Trial Locations

Locations (1)

Assaf Harofeh Medical Center; 🇮🇱 Beer Yakov, Israel